Renovorx Inc (RNXT)

$1.02 +0.03 (3.52%)
Market Cap 44.39M
Revenue (ttm) 1.12M
Net Income (ttm) -11.17M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -997.32%
Debt to Equity Ratio 0.00
Volume 197,400
Avg Vol 339,050
Day's Range N/A - N/A
Shares Out 45.05M
Stochastic %K 68%
Beta 1.22
Analysts Strong Sell
Price Target $6.88

Company Profile

RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in the developing of targeted combination therapies to enhance therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer. RenovoRx, Inc. was founded in 2009 and is headquartered in Mountain View, California.

Industry: Biotechnology
Sector: Healthcare
Phone: 650 284 4433
Fax: 650 397 4433
Address:
2570 West El Camino Real, Suite 320, Mountain View, United States
Aleleewy
Aleleewy Apr. 14 at 6:57 AM
Any thoughts about $RNXT and where is the direction 👀?
0 · Reply
Rnxtsavior
Rnxtsavior Apr. 11 at 10:57 AM
$RNXT So when the 13th comes and goes and still no one is interested in this sheeny man stock churner... what will be the next catalyst? 2027?
1 · Reply
Wolfietrader
Wolfietrader Apr. 10 at 9:05 PM
$RNXT good volume but…..
0 · Reply
JohnnieS
JohnnieS Apr. 10 at 5:44 PM
$RNXT
0 · Reply
enzomassimi
enzomassimi Apr. 10 at 12:57 PM
$RNXT It seems that today it wants to shoot up a lot
1 · Reply
Mrmaz138
Mrmaz138 Apr. 10 at 12:56 PM
$RNXT has some positive news out, and it looks like the stock is starting to get re-rated. Current price action suggests accumulation — worth keeping an eye on.
0 · Reply
enzomassimi
enzomassimi Apr. 10 at 12:53 PM
$RNXT is our day today !!!!
0 · Reply
Woodyp123
Woodyp123 Apr. 10 at 12:53 PM
$RNXT No to many people know about her I’m going to spread the news
0 · Reply
Woodyp123
Woodyp123 Apr. 10 at 12:52 PM
$RNXT just bought 2k shares I like this stock a whole lot
0 · Reply
enzomassimi
enzomassimi Apr. 10 at 12:47 PM
$RNXT yesssssssssssssss
0 · Reply
Latest News on RNXT
RenovoRx Secures First Notice of Allowance for Japanese Patent Covering its RenovoCath® Device for Targeted, Local Drug-Delivery via the Vasa Vasorum

Apr 8, 2026, 8:30 AM EDT - 5 days ago

RenovoRx Secures First Notice of Allowance for Japanese Patent Covering its RenovoCath® Device for Targeted, Local Drug-Delivery via the Vasa Vasorum

RenovoRx Named to Fast Company's Annual List of the World's Most Innovative Companies of 2026

Apr 1, 2026, 2:20 PM EDT - 12 days ago

RenovoRx Named to Fast Company's Annual List of the World's Most Innovative Companies of 2026

RenovoRx Reports Full Year 2025 Financial Results and Provides Business Update

Mar 30, 2026, 4:05 PM EDT - 14 days ago

RenovoRx Reports Full Year 2025 Financial Results and Provides Business Update

RenovoRx Announces Key Phase III Milestone: TIGeR-PaC Trial Surpasses 100 Randomized Patients as Study Nears Completion of Enrollment

Mar 26, 2026, 8:30 AM EDT - 18 days ago

RenovoRx Announces Key Phase III Milestone: TIGeR-PaC Trial Surpasses 100 Randomized Patients as Study Nears Completion of Enrollment

RenovoRx Announces Closing of Oversubscribed $10 Million at Market Private Placement

Mar 23, 2026, 8:30 AM EDT - 21 days ago

RenovoRx Announces Closing of Oversubscribed $10 Million at Market Private Placement

RenovoRx to Host Fourth Quarter and Full Year 2025 Financial Results and Business Highlights Conference Call on March 30th at 4:30 p.m. ET

Mar 20, 2026, 8:30 AM EDT - 24 days ago

RenovoRx to Host Fourth Quarter and Full Year 2025 Financial Results and Business Highlights Conference Call on March 30th at 4:30 p.m. ET

RenovoRx Announces $10 Million at Market Private Placement

Mar 18, 2026, 8:35 AM EDT - 26 days ago

RenovoRx Announces $10 Million at Market Private Placement

RenovoRx Advancing RenovoCath® Adoption at U.S. Cancer Centers, Strengthening Clinical and Commercial Momentum

Feb 27, 2026, 8:30 AM EST - 6 weeks ago

RenovoRx Advancing RenovoCath® Adoption at U.S. Cancer Centers, Strengthening Clinical and Commercial Momentum

RenovoRx Announces Acceptance of Clinical Data Abstract at 2026 Society of Interventional Radiology Annual Scientific Meeting

Feb 26, 2026, 8:30 AM EST - 6 weeks ago

RenovoRx Announces Acceptance of Clinical Data Abstract at 2026 Society of Interventional Radiology Annual Scientific Meeting

RenovoRx Establishes RenovoCath® Medical Advisory Board

Feb 10, 2026, 8:30 AM EST - 2 months ago

RenovoRx Establishes RenovoCath® Medical Advisory Board

RenovoRx Appoints Experienced Public Company Executive Mark Voll as Chief Financial Officer

Feb 5, 2026, 8:30 AM EST - 2 months ago

RenovoRx Appoints Experienced Public Company Executive Mark Voll as Chief Financial Officer

RenovoRx Announces Clinical Data Supporting the TAMP™ Therapy Platform will be Presented at the SIO 2026 Annual Scientific Meeting

Feb 4, 2026, 8:30 AM EST - 2 months ago

RenovoRx Announces Clinical Data Supporting the TAMP™ Therapy Platform will be Presented at the SIO 2026 Annual Scientific Meeting

RenovoRx Announces Acceptance of Clinical Data Abstract at 2026 Society of Interventional Oncology Annual Scientific Meeting

Jan 28, 2026, 8:30 AM EST - 2 months ago

RenovoRx Announces Acceptance of Clinical Data Abstract at 2026 Society of Interventional Oncology Annual Scientific Meeting

RenovoRx Expands RenovoCath® Commercial Adoption to Nine Active Cancer Centers Including City of Hope Cancer Center and Moffitt Cancer Center

Jan 20, 2026, 8:30 AM EST - 2 months ago

RenovoRx Expands RenovoCath® Commercial Adoption to Nine Active Cancer Centers Including City of Hope Cancer Center and Moffitt Cancer Center

RenovoRx to Participate in AlphaNorth Capital Event, January 16-18, 2026

Jan 14, 2026, 8:30 AM EST - 3 months ago

RenovoRx to Participate in AlphaNorth Capital Event, January 16-18, 2026

RenovoRx To Announce Promising New Clinical Data Using its TAMP™ Therapy Platform in an Abstract to be Presented at ASCO GI 2026

Jan 8, 2026, 8:30 AM EST - 3 months ago

RenovoRx To Announce Promising New Clinical Data Using its TAMP™ Therapy Platform in an Abstract to be Presented at ASCO GI 2026

RenovoRx Announces Acceptance of Clinical Data Abstract at the ASCO Gastrointestinal Cancers Symposium 2026

Dec 11, 2025, 8:30 AM EST - 4 months ago

RenovoRx Announces Acceptance of Clinical Data Abstract at the ASCO Gastrointestinal Cancers Symposium 2026

RenovoRx CEO Shaun Bagai to Present at iAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 on December 9th

Dec 1, 2025, 8:30 AM EST - 4 months ago

RenovoRx CEO Shaun Bagai to Present at iAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 on December 9th

RenovoRx CEO Shaun Bagai to Present at the Alliance Global Partners Emerging AgBiotech/Bio-Solutions Virtual Showcase on November 20th

Nov 19, 2025, 8:30 AM EST - 5 months ago

RenovoRx CEO Shaun Bagai to Present at the Alliance Global Partners Emerging AgBiotech/Bio-Solutions Virtual Showcase on November 20th

RenovoRx Reports Third Quarter 2025 Financial Results, Including Approximately $900,000 in Year-to-Date Revenue, and Provides Business Update

Nov 13, 2025, 4:05 PM EST - 5 months ago

RenovoRx Reports Third Quarter 2025 Financial Results, Including Approximately $900,000 in Year-to-Date Revenue, and Provides Business Update

RenovoRx Strengthens Scientific Advisory Board (SAB) with Pancreatic Cancer Expert Timothy Donahue, MD

Nov 6, 2025, 8:30 AM EST - 5 months ago

RenovoRx Strengthens Scientific Advisory Board (SAB) with Pancreatic Cancer Expert Timothy Donahue, MD

RenovoRx CEO Shaun Bagai to Participate at the Canaccord Genuity MedTech, Diagnostics & Digital Health & Services Forum on November 20th

Nov 4, 2025, 8:30 AM EST - 5 months ago

RenovoRx CEO Shaun Bagai to Participate at the Canaccord Genuity MedTech, Diagnostics & Digital Health & Services Forum on November 20th

RenovoRx to Host Third Quarter 2025 Financial Results and Business Highlights Conference Call on November 13th at 4:30 p.m. ET

Oct 27, 2025, 8:30 AM EDT - 6 months ago

RenovoRx to Host Third Quarter 2025 Financial Results and Business Highlights Conference Call on November 13th at 4:30 p.m. ET

RenovoRx Expands Scientific Advisory Board with Internationally Renowned Interventional Oncologist, Thierry de Baère, MD, PhD

Oct 9, 2025, 8:30 AM EDT - 6 months ago

RenovoRx Expands Scientific Advisory Board with Internationally Renowned Interventional Oncologist, Thierry de Baère, MD, PhD

RenovoRx's PanTheR Post-Marketing Registry Study Progresses with First Clinical Procedure and Addition of Two Participating Clinical Sites

Sep 25, 2025, 8:30 AM EDT - 7 months ago

RenovoRx's PanTheR Post-Marketing Registry Study Progresses with First Clinical Procedure and Addition of Two Participating Clinical Sites

RenovoRx CEO Shaun Bagai to Present at iAccess Alpha Virtual Best Ideas Fall Investment Conference 2025 on September 16th

Sep 11, 2025, 8:30 AM EDT - 7 months ago

RenovoRx CEO Shaun Bagai to Present at iAccess Alpha Virtual Best Ideas Fall Investment Conference 2025 on September 16th

RenovoRx CEO Shaun Bagai to Present at H.C. Wainwright's 27th Annual Global Investment Conference in New York City, September 8-10, 2025

Aug 20, 2025, 8:30 AM EDT - 8 months ago

RenovoRx CEO Shaun Bagai to Present at H.C. Wainwright's 27th Annual Global Investment Conference in New York City, September 8-10, 2025

RenovoRx Reports Commercial Revenue Growth in the Second Quarter 2025 and Announces Positive Independent Data Monitoring Committee Recommendation to Continue Pivotal Phase III TIGeR-PaC Trial Based on Interim Data Review

Aug 14, 2025, 4:05 PM EDT - 8 months ago

RenovoRx Reports Commercial Revenue Growth in the Second Quarter 2025 and Announces Positive Independent Data Monitoring Committee Recommendation to Continue Pivotal Phase III TIGeR-PaC Trial Based on Interim Data Review

RenovoRx Expands U.S. Commercialization Efforts for the RenovoCath® Device with Growing Customer Demand and Key Leadership Hire

Aug 6, 2025, 8:30 AM EDT - 8 months ago

RenovoRx Expands U.S. Commercialization Efforts for the RenovoCath® Device with Growing Customer Demand and Key Leadership Hire

RenovoRx Launches Multi-Center Post-Marketing Registry Study to Evaluate Cancer Treatment Delivered by RenovoCath® Device to Solid Tumors

Jul 28, 2025, 8:30 AM EDT - 9 months ago

RenovoRx Launches Multi-Center Post-Marketing Registry Study to Evaluate Cancer Treatment Delivered by RenovoCath® Device to Solid Tumors

RenovoRx to Host Second Quarter 2025 Financial Results and Business Highlights Conference Call on August 14th at 4:30 p.m. ET

Jul 14, 2025, 8:30 AM EDT - 9 months ago

RenovoRx to Host Second Quarter 2025 Financial Results and Business Highlights Conference Call on August 14th at 4:30 p.m. ET

RenovoRx Reports First Quarter 2025 Financial Results and Business Highlights

May 15, 2025, 4:05 PM EDT - 11 months ago

RenovoRx Reports First Quarter 2025 Financial Results and Business Highlights

RenovoRx to Participate in Fireside Chat at A.G.P. Virtual Healthcare Company Showcase on May 21st

May 14, 2025, 8:30 AM EDT - 11 months ago

RenovoRx to Participate in Fireside Chat at A.G.P. Virtual Healthcare Company Showcase on May 21st

U.S. Patent Office Issues New Patent to RenovoRx for Novel Trans-Arterial Micro-Profusion (TAMP™) Therapy Platform

May 6, 2025, 8:30 AM EDT - 1 year ago

U.S. Patent Office Issues New Patent to RenovoRx for Novel Trans-Arterial Micro-Profusion (TAMP™) Therapy Platform

RenovoRx to Host First Quarter 2025 Financial Results Conference Call on May 15th at 4:30 p.m. ET

May 1, 2025, 8:30 AM EDT - 1 year ago

RenovoRx to Host First Quarter 2025 Financial Results Conference Call on May 15th at 4:30 p.m. ET

Johns Hopkins Medicine Initiates Patient Enrollment for RenovoRx's Ongoing Phase III TIGeR-PaC Clinical Trial

Apr 29, 2025, 8:30 AM EDT - 1 year ago

Johns Hopkins Medicine Initiates Patient Enrollment for RenovoRx's Ongoing Phase III TIGeR-PaC Clinical Trial

RenovoRx Increases U.S. Production of RenovoCath® Devices to Meet Growing Demand from Oncology Community

Apr 16, 2025, 8:30 AM EDT - 1 year ago

RenovoRx Increases U.S. Production of RenovoCath® Devices to Meet Growing Demand from Oncology Community

RenovoRx to Present at LD Micro Invitational XV Conference in New York on April 10th

Apr 4, 2025, 8:30 AM EDT - 1 year ago

RenovoRx to Present at LD Micro Invitational XV Conference in New York on April 10th

RenovoRx Reports Initial Revenues from RenovoCath® Commercialization, and Provides Update on Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial

Apr 1, 2025, 8:30 AM EDT - 1 year ago

RenovoRx Reports Initial Revenues from RenovoCath® Commercialization, and Provides Update on Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial

RenovoRx Highlights New Human Pharmacokinetic Data Abstract at SSO 2025 Annual Meeting

Mar 28, 2025, 8:00 AM EDT - 1 year ago

RenovoRx Highlights New Human Pharmacokinetic Data Abstract at SSO 2025 Annual Meeting

RenovoRx Pre-Clinical Results Supporting TAMP™ as a Targeted Locoregional Drug Delivery Platform to Receive Award at SIR 2025 Annual Scientific Meeting

Mar 26, 2025, 8:00 AM EDT - 1 year ago

RenovoRx Pre-Clinical Results Supporting TAMP™ as a Targeted Locoregional Drug Delivery Platform to Receive Award at SIR 2025 Annual Scientific Meeting

RenovoRx CEO to Provide Strategic Update During Fireside Chat on Thursday, April 3rd at 12:00 p.m. ET

Mar 20, 2025, 8:00 AM EDT - 1 year ago

RenovoRx CEO to Provide Strategic Update During Fireside Chat on Thursday, April 3rd at 12:00 p.m. ET

RenovoRx Announces Abstract Presentation at the Society of Surgical Oncology (SSO) 2025

Mar 19, 2025, 8:00 AM EDT - 1 year ago

RenovoRx Announces Abstract Presentation at the Society of Surgical Oncology (SSO) 2025

RenovoRx Advances Commercialization of RenovoCath® with Several New Purchase Orders, Including Customer Reorders

Feb 26, 2025, 8:00 AM EST - 1 year ago

RenovoRx Advances Commercialization of RenovoCath® with Several New Purchase Orders, Including Customer Reorders

RenovoRx Highlights Promising Pre-Clinical Data Abstract: TAMP™ Therapy Platform Offers Potential to Improve Localized and Targeted Drug Delivery

Feb 13, 2025, 8:00 AM EST - 1 year ago

RenovoRx Highlights Promising Pre-Clinical Data Abstract: TAMP™ Therapy Platform Offers Potential to Improve Localized and Targeted Drug Delivery

RenovoRx Announces Closing of $12.1 Million Underwritten Public Offering of Common Stock

Feb 11, 2025, 7:00 AM EST - 1 year ago

RenovoRx Announces Closing of $12.1 Million Underwritten Public Offering of Common Stock

RenovoRx Announces Pricing of $12.1 Million Underwritten Public Offering of Common Stock

Feb 6, 2025, 8:49 PM EST - 1 year ago

RenovoRx Announces Pricing of $12.1 Million Underwritten Public Offering of Common Stock

RenovoRx Announces Proposed Public Offering

Feb 6, 2025, 4:05 PM EST - 1 year ago

RenovoRx Announces Proposed Public Offering

RenovoRx Highlights Promising Pharmacokinetic Data Abstract Presented at ASCO GI 2025

Jan 27, 2025, 8:00 AM EST - 1 year ago

RenovoRx Highlights Promising Pharmacokinetic Data Abstract Presented at ASCO GI 2025

RenovoRx Announces Acceptance of Abstract for Presentation at ASCO Gastrointestinal Cancers Symposium 2025

Jan 8, 2025, 8:00 AM EST - 1 year ago

RenovoRx Announces Acceptance of Abstract for Presentation at ASCO Gastrointestinal Cancers Symposium 2025

Aleleewy
Aleleewy Apr. 14 at 6:57 AM
Any thoughts about $RNXT and where is the direction 👀?
0 · Reply
Rnxtsavior
Rnxtsavior Apr. 11 at 10:57 AM
$RNXT So when the 13th comes and goes and still no one is interested in this sheeny man stock churner... what will be the next catalyst? 2027?
1 · Reply
Wolfietrader
Wolfietrader Apr. 10 at 9:05 PM
$RNXT good volume but…..
0 · Reply
JohnnieS
JohnnieS Apr. 10 at 5:44 PM
$RNXT
0 · Reply
enzomassimi
enzomassimi Apr. 10 at 12:57 PM
$RNXT It seems that today it wants to shoot up a lot
1 · Reply
Mrmaz138
Mrmaz138 Apr. 10 at 12:56 PM
$RNXT has some positive news out, and it looks like the stock is starting to get re-rated. Current price action suggests accumulation — worth keeping an eye on.
0 · Reply
enzomassimi
enzomassimi Apr. 10 at 12:53 PM
$RNXT is our day today !!!!
0 · Reply
Woodyp123
Woodyp123 Apr. 10 at 12:53 PM
$RNXT No to many people know about her I’m going to spread the news
0 · Reply
Woodyp123
Woodyp123 Apr. 10 at 12:52 PM
$RNXT just bought 2k shares I like this stock a whole lot
0 · Reply
enzomassimi
enzomassimi Apr. 10 at 12:47 PM
$RNXT yesssssssssssssss
0 · Reply
enzomassimi
enzomassimi Apr. 10 at 12:46 PM
$RNXT news probably
0 · Reply
enzomassimi
enzomassimi Apr. 10 at 12:45 PM
$RNXT buy buy start today
0 · Reply
suredubb
suredubb Apr. 9 at 3:15 PM
$RNXT someone is buybig.. does’t feel like retail
1 · Reply
suredubb
suredubb Apr. 8 at 8:11 PM
$RNXT patents in japan commercializing in USA This is a big deal… executing
1 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Apr. 8 at 7:11 PM
$RNXT RSI: 41.77, MACD: 0.0079 Vol: 0.10, MA20: 0.99, MA50: 0.95 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
TheTradeXchange
TheTradeXchange Apr. 8 at 12:31 PM
$RNXT - RenovoRx Secures First Notice of Allowance for Japanese Patent Covering its RenovoCath® Device for Targeted, Local Drug-Delivery via the Vasa Vasorum
1 · Reply
NomadEx
NomadEx Apr. 8 at 11:38 AM
$RNXT ready to move higher… lots off of market action not priced in yet.
0 · Reply
suredubb
suredubb Apr. 7 at 8:04 AM
$RNXT just did $10 million dollar private placement and it was oversubscribed, which is huge strategic life science investors, BOD, management, etc great time to scale in
0 · Reply
suredubb
suredubb Apr. 7 at 7:48 AM
$RNXT strong buy… $8 pt i love early stage bio great time to scale in
0 · Reply
BA777
BA777 Apr. 6 at 5:56 PM
$RNXT Slowly getting a position built. I like this one.
0 · Reply
KUMO2026
KUMO2026 Apr. 6 at 11:03 AM
$RNXT RS will take place in 2026
1 · Reply
focafoca99
focafoca99 Apr. 1 at 9:45 PM
$RNXT made Fast Company's 2026 most-innovative list in medical devices, which it is using to reinforce the commercial traction story around RenovoCath.
0 · Reply